Clinical Trials
60 trialsA Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Exelixis
MOMENTUM-1
RTOG Foundation, Inc.
Cabozantinib for Patients With Recurrent or Progressive Meningioma
Baptist Health South Florida
MIRAGE
Istituto Oncologico Veneto IRCCS
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Alliance for Clinical Trials in Oncology
INTUITT-NF2
Massachusetts General Hospital
EViDENCE-BT
University of Zurich
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
Mayo Clinic
A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
Jazz Pharmaceuticals
Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma
University of California, San Francisco
Abemaciclib in Newly Diagnosed Meningioma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
NYU Langone Health
Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC
Weill Medical College of Cornell University
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
Emory University
Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma
Massachusetts General Hospital
An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma
Dana-Farber Cancer Institute
A Study of ONC201 for Refractory Meningioma
University of Nebraska
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Reveal Pharmaceuticals Inc.
CBT-I in PBT
Virginia Commonwealth University
LUMEN-1
European Organisation for Research and Treatment of Cancer - EORTC
Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors
Memorial Sloan Kettering Cancer Center
Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers
National Institutes of Health Clinical Center (CC)
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
Northwestern University
Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System
Cedars-Sinai Medical Center
SEL-TH-1601
Children's Hospital Medical Center, Cincinnati
ELUMEN
Central Hospital, Nancy, France
A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma
Rabin Medical Center
AFBTEdema
Skane University Hospital
FG001 in Subjects with Meningiomas or Presumed Low-Grade Gliomas Scheduled for Neurosurgery
Rigshospitalet, Denmark
Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma
Radiation Therapy Oncology Group
CEVOREM
Assistance Publique Hopitaux De Marseille
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
University of Iowa
Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas
Massachusetts General Hospital
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
Massachusetts General Hospital
Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
SCRI Development Innovations, LLC
Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors
Wake Forest University Health Sciences
Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor
Wake Forest University Health Sciences
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
National Institutes of Health Clinical Center (CC)
Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma
UNICANCER
Radiation Therapy in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Grade II or Grade III Meningioma
European Organisation for Research and Treatment of Cancer - EORTC
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Northwestern University
Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas
Medical College of Wisconsin
Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
Northwestern University
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Monthly SOM230C for Recurrent or Progressive Meningioma
Dana-Farber Cancer Institute
Dosimetry Guided PRRT With 90Y-DOTATOC
University of Iowa
Antineoplaston Therapy in Treating Patients With Meningioma
Burzynski Research Institute
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
NYU Langone Health
Imatinib Mesylate in Treating Patients With Recurrent Meningioma
National Cancer Institute (NCI)
Combination of Hydroxyurea and Verapamil for Refractory Meningiomas
University of Utah